| Budget Amount *help |
¥5,460,000 (Direct Cost: ¥4,200,000、Indirect Cost: ¥1,260,000)
Fiscal Year 2013: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2012: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2011: ¥2,860,000 (Direct Cost: ¥2,200,000、Indirect Cost: ¥660,000)
|
|---|
| Research Abstract |
We found that, although TRAP-stimulated platelets could induce up-regulation of some molecules such as CD40, CD80, CD83, CD86 and HLA-DR to some extent, the addition of MPs further increased this expression compared with expression induced by TRAP-stimulated platelets. In addition, the enhancement of expression of these molecules in response to TRAP-stimulated platelets or MPs was completely inhibited by anti-CD154 antibody. For DIC patients with hematologic malignancy, univariate analysis showed that PT, fibrinogen, CRP, PDMP, EDMP, sCD40L, IL-6, TNF-alpha, RANTES and MCP-1 were significantly associated with HMGB1. DIC patients exhibited significant decrease in HMGB1 levels after rTM therapy. In addition, the levels of platelet activation markers and cytokines were significantly decreased after rTM therapy in DIC patients. Our findings indicate the role of EDMP and HMGB1 in DIC patients with hematologic malignancy.
|
